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TO THE EDITOR
Cockayne syndrome (CS) is character-
ized by various clinical manifestations
such as postnatal growth failure and
progressive neurological dysfunction,
but it conveys no predisposition to skin
cancer. CS can be caused by mutation
in two genes, CKN1/CSA and ERCC6/
CSB. CSA and CSB protein play a key
role in transcription-coupled DNA re-
pair, which removes UV-induced DNA
lesions only in the actively transcribed
DNA strand (Hanawalt, 2002). CS was
classified into three clinical subtypes:
classical, severe, and mild CS (Nance
and Berry, 1992). The clinical diagnosis
of classical CS requires the presence of
growth failure, neurological dysfunc-
tion, and at least three of the following:
photosensitivity, pigmentary retinopa-
thy, sensorineural hearing loss, dental
caries, and cachectic dwarfism. Mild
CS patients have some of the clinical
signs of CS but lack one or more of the
criteria, and their symptoms are mild or
late in onset. Mild CS patients also have
normal reproductive capacity.
As clinical symptoms of CS are not
associated with cellular UV hyper-
sensitivity (Lehmann, 2003), some recent
investigations have focused on activi-
ties of CSB, other than transcription-
coupled DNA repair, that might be
responsible for CS characteristics. CSB
interacts with many proteins and thus
has many possible functions (Licht
et al., 2003). Importantly, cells from
patients accumulate oxidative DNA
lesions after X-ray exposure (Tuo
et al., 2001), and the repair deficiency
of oxidative lesions is corrected by
expression of formamidopyrimidine
DNA glycosylase from Escherichia coli
(Ropolo et al., 2007).
Some CS patients rarely show slower
course than usual, resulting in survival
into adulthood (Rapin et al., 2006). We
present herein a patient with CS, named
KPSX6, who was a 49-year-old Japa-
nese woman with a history of freckling
and dry skin in sun-exposed areas,
which had developed since her teens
(Figure 1). Although she showed normal
mental development, she had growth
retardation similar to that of her five
siblings. Four siblings had no skin
lesions, but her sister had pigmentation.
Her parents were consanguineous. She
had two daughters who were normal.
When she was 47 years old, her family
noted dementia, ataxia, and hearing
loss, which had progressed over 2
years. Physical examination revealed
a remarkably small body (height,
131.7 cm; weight, 33.1 kg) with an
aged face and scoliosis. Her skin was
dry and pigmented on the neck, arms,
and legs. However, there were no skin
cancer lesions, and her hair was nor-
mal. On neurological examination, the
deep tendon reflexes were indicative of
asthenia. Her muscles showed hypo-
tonus but no atrophy, and she had
difficulty in walking. Sensory examina-
tion revealed no abnormalities, and the
cranial nerve examination was normal.
She had difficulty with hearing and
speech. She exhibited intracranial cal-
cification on computed tomography
and cerebellar atrophy on magnetic
resonance imaging. There were no
findings on ophthalmologic examina-
tion. The minimal erythema dose
Figure 1. Clinical manifestation of patient KPSX6. Photograph of the (a) face and (b) arm.
Abbreviations: CS, Cockayne syndrome; UVSS, UV-sensitive syndrome
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(40mJ cm2) of UV radiation revealed
hypersensitivity to UVB, but reactivity
to UVA was normal. There was no
delayed reaction to UVB. Thus, the
patient described herein was clinically
classified as having mild CS.
Fibroblasts derived from this patient
showed normal unscheduled DNA
synthesis but defective recovery of
RNA synthesis, and complementation
test by a host-cell reactivation assay
revealed that KPSX6 cells belonged to
CS complementation group B (Table 1
and Figure S1). Our patient had not
displayed neurological abnormalities
until the age of 47 years and had
survived well beyond the usual lifetime
for CS-B patients. In considering our
results and those of others, we hypo-
thesized that the response to oxidative
stress differed between our patient and
those with the classical form of CS-B.
To confirm this, survival in the presence
of H2O2 was compared among KPSX6
cells (mild form of CS-B), CS1MO cells
(classical form of CS-B), and Turu cells
(normal fibroblasts). Although UV sensiti-
vity was similar between KPSX6 and
CS1MO cells (Figure 2a), H2O2 sensi-
tivity in KPSX6 cells was lower than that
in CS1MO cells and higher than that in
Turu cells (Figure 2b). Therefore, it is
possible that the relatively mild CS
symptoms in this patient are due to an
intermediate sensitivity to oxidative
stress.
Our results at the cellular level
prompted an examination of the CSB
gene mutation in KPSX6. We isolated
the CSB cDNA derived from KPSX6
cells by reverse transcription-PCR. Se-
quencing of the PCR product and
reverse transcription-PCR restriction
fragment length polymorphism analysis
revealed a homozygous deletion of four
nucleotides (CGAC) from a tandem
CGAC repeat at positions 304–311
(bold faced characters in Table 2 and
Figure S2). This deletion resulted in a
frameshift of the mRNA, which inserted
a stop codon five amino acids down-
stream, at amino-acid position 82, and
prevented the detectable expression of
a CSB polypeptide (Figure S3). Studies
have reported many mutations in CS-B
patients, but there are no genetic data
from patients with mild symptoms of
CS-B (Spivak, 2004). To the best of our
knowledge, the present report is the first
analysis of a mutation from a patient
with a mild form of CS-B. Moreover,
this null mutation in the CSB gene was
located near the mutation of UV-
sensitive syndrome (UVSS)-1KOSV
cells, which belong to the UVSS/CS-B
category (Horibata et al., 2004).
UVSS is characterized by mild skin
manifestations without neurological ab-
normalities or skin cancer (Itoh et al.,
1994). UVSS cells show UV sensitivity
and failure of recovery of RNA synth-
esis after UV irradiation, but have a
normal level of unscheduled DNA
synthesis, similar to that in CS cells
(Table 1). It was recently reported that
one UVSS cell line, UVS1KO, has a
Table 1. Characteristics of CS, UVSS, and patient
CS UVSS Patient
Clinical features
Acute sunburn + + +
Skin tumors   
Freckling  + +
Neurological findings +  +
Growth failure +  +
Laboratory findings
UV sensitivity + + +
Depression of UDS   
Depression of RRS + + +
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Figure 2. Survival after UV irradiation or oxidative stress. Appropriate numbers of cells were plated
in 100mm dishes. After (a) UV irradiation or (b) H2O2 treatment for 1 hour, the cells were incubated
for 14 days, fixed, and stained with Giemsa. Each point represents an average of three experiments as
mean±SD. Turu cells (J) were used as a normal control. KPSX6 cells (&), CS1MO cells (n).
Table 2. Mutation of the CSB gene in patient KPSX6
Normal
Amino acid 75 I D R H Q I Q A V E
cDNA 302 ATC GAC CGA CAT CAG ATC CAG GCA GTA GAG
Patient
Amino acid 75 I D I R S R Q Stop
cDNA 302 ATC GAC ATC AGA TCC AGG CAG TAG
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mutation in the CSB gene, which
suggests a possible explanation for the
discrepancy in the genotype–phenotype
relationship (Horibata et al., 2004).
Spivak (2005) has demonstrated that
UVSS comprises at least two comple-
mentation groups: UVSS/CS-B, with a
mutation in CSB gene, and UVSS/A,
with a mutation in an unidentified
gene. Two UVSS/CS-B patients, UVSS1-
KO and CS3AM, have been reported to
carry the same CSB mutation, that is,
the nonsense mutation CGA308:Arg77 to
TGA308:stop (Miyauchi-Hashimoto
et al., 1998, K. Tanaka, personal com-
munication).
We propose two possibilities to
explain why patient KPSX6 had CS
symptoms such as neurological ab-
normalities, whereas patients UVSS1KO
and CS3AM did not, despite the
presence of a null mutation of the CSB
gene in KPSX6, UVSS1KO, and CS3AM
cells. First, the transiently produced
mRNA or polypeptides of various
lengths transcribed from the CSB gene
in KPSX6, UVSS1KO, and CS3AM may
reflect a different response to oxidative
stress. Alternatively, patients UVSS1KO
and CS3AM may develop neurological
symptoms in the future. Some neurolo-
gical abnormalities did not appear in
patient KPSX6 until the age of 47 years.
At the time of reporting, patients
UVSS1KO and CS3AM were 33 and
13 years old, respectively. Continued
follow-up of the two patients UVSS1KO
and CS3AM may clarify our hypothesis,
as might further studies focusing on the
response after oxidative stress in CS-B
and UVSS/CS-B cells.
This study was approved by the
medical ethical committee of the Uni-
versity of Kumamoto and was con-
ducted according to the Declaration of
Helsinki Principles. Informed consent
was obtained from patients.
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Figure S1. Characterization of KPSX6 cells.
Figure S2. Mutation analysis of the CSB gene in
KPSX6.
Figure S3. Western blot analysis of the CSB
protein in KPSX6 cells.
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TO THE EDITOR
Psoriasis is a chronic skin disease with
typical histopathologic findings of epi-
dermal hyperplasia and vascular
changes. Vascular endothelial growth
factors (VEGFs) are potent stimulators of
the angiogenesis affecting endothelial
cell proliferation, motility, and vascular
permeability, and they are crucial
regulators of vascular development
during embryogenesis as well as for
blood vessel formation in adults.
Abbreviations: LD, linkage disequilibrium; SNP, single-nucleotide polymorphism; VEGF, vascular
endothelial growth factor
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